Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM.
Sausville EA, et al. Among authors: messmann r.
J Clin Oncol. 2001 Apr 15;19(8):2319-33. doi: 10.1200/JCO.2001.19.8.2319.
J Clin Oncol. 2001.
PMID: 11304786
Clinical Trial.